Style | Citing Format |
---|---|
MLA | Safarirad M, et al.. "The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies." Endocrine# Metabolic and Immune Disorders - Drug Targets, vol. 21, no. 11, 2021, pp. 2099-2103. |
APA | Safarirad M, Ganji AA, Fekrvand S, Yazdani R, Motlagh AV, Abolhassani H, Aghamohammadi A (2021). The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies. Endocrine# Metabolic and Immune Disorders - Drug Targets, 21(11), 2099-2103. |
Chicago | Safarirad M, Ganji AA, Fekrvand S, Yazdani R, Motlagh AV, Abolhassani H, Aghamohammadi A. "The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies." Endocrine# Metabolic and Immune Disorders - Drug Targets 21, no. 11 (2021): 2099-2103. |
Harvard | Safarirad M et al. (2021) 'The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies', Endocrine# Metabolic and Immune Disorders - Drug Targets, 21(11), pp. 2099-2103. |
Vancouver | Safarirad M, Ganji AA, Fekrvand S, Yazdani R, Motlagh AV, Abolhassani H, et al.. The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies. Endocrine# Metabolic and Immune Disorders - Drug Targets. 2021;21(11):2099-2103. |
BibTex | @article{ author = {Safarirad M and Ganji AA and Fekrvand S and Yazdani R and Motlagh AV and Abolhassani H and Aghamohammadi A}, title = {The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies}, journal = {Endocrine# Metabolic and Immune Disorders - Drug Targets}, volume = {21}, number = {11}, pages = {2099-2103}, year = {2021} } |
RIS | TY - JOUR AU - Safarirad M AU - Ganji AA AU - Fekrvand S AU - Yazdani R AU - Motlagh AV AU - Abolhassani H AU - Aghamohammadi A TI - The First Case Report of Kabuki Syndrome From the National Iranian Registry of Primary Immunodeficiencies JO - Endocrine# Metabolic and Immune Disorders - Drug Targets VL - 21 IS - 11 SP - 2099 EP - 2103 PY - 2021 ER - |